Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Santhera Pharmaceuticals : Meets Primary Endpoint For Vamorolone In Duchenne Muscular Dystrophy; Shares Soar 50%

06/01/2021 | 06:48am EDT


ę MT Newswires 2021
All news about SANTHERA PHARMACEUTICALS HOLDING AG
06/24SANTHERA PHARMACEUTICALS' : Vamorolone Shows Positive Results In Duchenne Muscul..
MT
06/24PRESS RELEASE : Santhera and ReveraGen to Present -2-
DJ
06/24PRESS RELEASE : Santhera and ReveraGen to Present Findings from Pivotal VISION-D..
DJ
06/24Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with..
DJ
06/24Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. to Present Findings fr..
CI
06/24Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with..
GL
06/23SANTHERA PHARMACEUTICALS : Shareholders Approve all Board Proposals at Today's A..
AQ
06/23SANTHERA PHARMACEUTICALS' : Trial For Raxone Meets Primary Endpoint In Vision Lo..
MT
06/23PRESS RELEASE : Santhera Announces Phase 4 LEROS Trial with Raxone(R) Met Primar..
DJ
06/23Santhera Announces Phase 4 LEROS Trial with Raxone(R) Met Primary Endpoint in..
DJ
More news
Financials
Sales 2021 16,8 M 18,3 M 18,3 M
Net income 2021 -38,1 M -41,6 M -41,6 M
Net cash 2021 1,00 M 1,09 M 1,09 M
P/E ratio 2021 -2,40x
Yield 2021 -
Capitalization 55,5 M 60,7 M 60,6 M
EV / Sales 2021 3,25x
EV / Sales 2022 0,66x
Nbr of Employees 86
Free-Float 83,0%
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANTHERA PHARMACEUTICALS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Last Close Price 2,30 CHF
Average target price 6,40 CHF
Spread / Average Target 178%
EPS Revisions
Managers and Directors
Dario Eklund Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Elmar J. Schnee Chairman
Martin Gertsch Vice Chairman
Philipp Gutzwiller Independent Director